A liquid formulation of a therapeutic agent comprising: a taxane in a pharmaceutically effective dosage; and one or more pharmaceutically acceptable solubility enhancers is disclosed. The liquid formulation may further comprise stabilizers. The taxane in solution may be in the range 0.05 mg/ml to 5 mg/ml. An injectable formulation of a therapeutic agent comprising: a taxane in a pharmaceutically effective dosage; and one or more pharmaceutically acceptable solubility enhancers is also described. The concentration of the taxane in suspension may be in the range from about 1 mg/ml to about 15 mg/ml.